Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus PROMETH FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus PROMETH FORTIS.
LEVOCETIRIZINE HYDROCHLORIDE vs PROMETH FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective peripheral histamine H1-receptor antagonist. It inhibits the effects of histamine at the H1 receptor, reducing allergic symptoms such as itching, sneezing, and rhinorrhea. It has lower affinity for central H1 receptors and anticholinergic properties compared to first-generation antihistamines.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, with additional anticholinergic, antiemetic, and sedative properties. It blocks histamine at H1 receptors, reducing allergic symptoms and motion sickness, and exerts antiemetic effects by blocking dopamine D2 receptors in the chemoreceptor trigger zone.
Oral, 5 mg once daily in the evening.
Adults: 12.5-25 mg intramuscular or intravenous every 4-6 hours as needed for nausea. For severe nausea up to 50 mg IM/IV. Maximum single dose 50 mg, maximum daily dose 200 mg.
None Documented
None Documented
Terminal elimination half-life: 7–8 hours in healthy adults; prolonged to 20–24 hours in renal impairment (CrCl <40 mL/min); clinically, stable levels require 2–3 days.
Terminal elimination half-life: 9–16 hours (mean ~12 hours). In children and elderly, half-life may be prolonged (up to 20 hours).
Approximately 85% renal excretion as unchanged drug via glomerular filtration and tubular secretion, 12.9% fecal excretion, <1% biliary.
Primarily renal as inactive metabolites; <1% excreted unchanged. Total elimination: renal ~70%, fecal ~30%.
Category A/B
Category C
Antihistamine
Antihistamine